Studies involving the ARE-BP tristetraprolin (TTP) have largely focused on its role in lipopolysaccharide (LPS)-treated myeloid cells, with little understanding of its role in type I/type III IFN regulation or following viral infection. This evidence concerns the gene SGCG and viral infectious disease.